Matthew Rabinowitz: I Can Think of No One Better to Lead Natera into Its Next Chapter

Natera and Incyte are collaborating on a Phase II trial (NCT07823322) for Incyte's immunotherapy INCA33890 in colorectal cancer. Natera's Signatera will monitor minimal residual disease. Natera will provide trial design and patient matching services. Both companies aim to address unmet needs in colorectal cancer treatment.

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.

Natera (NTRA) and Incyte (INCY) are collaborating on a phase II colorectal cancer study. The trial will use Natera's Signatera test to guide treatment with Incyte's investigational immunotherapy INCA33890. Patients testing positive for minimal residual disease (MRD) post-treatment may be eligible. Natera will provide trial matching services.

Natera (NTRA) set a $6B revenue target for 2029, driven by oncology testing and international growth. It raised 2026 revenue guidance to $3.005-$3.035B. Q3 2026 saw a 34.1% revenue increase to $794M but a wider adjusted loss of $0.39 per share. Management expects continued investment in R&D and commercial initiatives.

Natera reported a Q3 2026 adjusted loss of 39 cents per share, wider than expected, but revenues of $794M beat estimates. Oncology and women's health drove growth, with total tests up 34.1% YoY. The company raised 2026 revenue guidance to $3.005B-$3.035B. Gross margin improved, but operating loss narrowed. Cash flow remained positive.

NTRA raised its 2026 revenue guidance to $3.02B from $2.88B, with Q3 sales up 22.3% YoY. Operating margin improved to -8.6% from -16.5%. CEO Steve Chapman stepped down, replaced by Solomon Moshkevich. Oncology and MRD testing volumes surged 56%, while women's and organ health grew. Pharma and data revenues rose 70% YoY, but investments may pressure margins.